In which clinical situations, if any, would you still consider carboplatin-paclitaxel alone rather than chemoimmunotherapy for first-line treatment of metastatic squamous anal cancer after POD1UM-303/InterAACT-2?
Rao et al., PMID 42097353
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Harvard Medical School
Answered on
I think there are still rare patients who have significant autoimmune conditions requiring DMARDs or steroids where I would forgo IO. Otherwise, would routinely offer.
Join for free or sign in to see the full answer